InterCure Ltd.

NASDAQ:INCR

Drug Manufacturers - Specialty & Generic

Healthcare
$3.98 -3.97%

-$0.04 today

Market cap
$51.63M
Beta
0.57
P/E (TTM)
-4.3
EPS (TTM)
-$0.64
52W Low $0.68High $1.77

Volume 0.01M

Average 0.04M

INCR Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

InterCure Ltd.NASDAQ: INCR

Financing Cash Flow · Q2 FY2025 · quarter ended Jun 2025

Financing cash flow declines year over year

Q2 FY2025 financing cash flow of ₪17.42M (cash outflow) fell 28.6% year over year, in line with the -28.6% change in trailing-twelve-month financing cash flow. Sequentially, it rose 0.0% from the prior quarter.

Context

  • Financing cash flow amounted to 17.3% of revenue in FY2025, up 6.2 pp from a year earlier.
  • Financing cash flow increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -28.6% holds above the trailing-twelve-month pace of -28.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2025
-₪17.42M+0.0% QoQ
Last fiscal yearDec 2025
-₪46.66M-276.4% YoY
LTMJun 2025
-₪34.85M-28.6% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-28.6%——
1 year-276.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

ILS · from the cash flow

Latest · FY2025
(46.66M) ILS
Year-over-year change
-276.4%

Financing Cash Flow vs competitors

How INCR compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -28.6% is the 6th highest of 9, against a peer median of +5.4%.
  • Financing cash flow amounts to 14.3% of revenue for INCR, versus a peer median of 1.1%.
INCR Competitors
Financing Cash Flow for INCR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026$76.1M USD+6.1%—1934.4%
BMEABiomea Fusion, Inc.LTM Mar 2026$64.53M USD+1243.2%+279.8%—
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026$63.49M USD+3167.7%——
INCRInterCure Ltd.LTM Jun 2025₪34.85M ILS-28.6%—14.3%
CRDLCardiol Therapeutics Inc.LTM Mar 2026CA$29.19M CAD+55.7%——
FBIOFortress Biotech, Inc.LTM Mar 2026$2.09M USD-102.2%+0.9%3.2%
AMWLAmerican Well CorporationLTM Mar 2026$600K USD-38.0%—0.3%
ASRTAssertio Holdings, Inc.LTM Mar 2026$267K USD+4.7%-71.1%0.3%
HYFTMindWalk Holdings Corp.LTM Jan 2026CA$201.94K CAD-98.8%+72.9%1.1%
Peer median (excluding INCR) —+5.4%+36.9%1.1%

Competitors are the stored peer set for INCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

ILS
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income7.3M43.75M(63.53M)(72.79M)(36.78M)
Depreciation & Amortization7.39M11.7M13.17M15.37M17.15M
Deferred Income Tax11.44M93K2.25M(14.53M)(7.32M)
Stock-Based Compensation6.45M8.91M2.59M2.28M2.43M
Change in Working Capital(1.65M)(3.02M)(43.55M)(9.19M)18.88M
Accounts Receivables8.39M(18.29M)(23.49M)13.26M9.29M
Inventory(17.89M)(75.99M)40.21M(17.44M)15.95M
Accounts Payables2.79M57.03M(47.63M)(8.9M)(8.82M)
Other Working Capital5.06M34.22M(12.63M)3.88M2.46M
Other Non-Cash Items(5.91M)(10.16M)35.44M11.94M22.49M
Operating Cash Flow25.02M51.27M(53.63M)(66.93M)16.84M
Capital Expenditures(14.03M)(19.74M)(2.62M)(4.38M)(3.55M)
Acquisitions (Net)(19.09M)(8.32M)(4.2M)405K1.67M
Purchases of Investments(1.25M)0000
Sales of Investments00000
Other Investing Activities(30.84M)(114.44M)11.59M21.66M(107K)
Investing Cash Flow(65.21M)(142.5M)4.77M17.69M(1.99M)
Debt Repayment65.83M137.73M(61.98M)7.74M(29.13M)
Common Stock Issued128.73M0034M1.5M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.38M(17.28M)(20.91M)(15.29M)(19.03M)
Financing Cash Flow197.94M120.45M(82.89M)26.46M(46.66M)
Effect of Forex Changes(4.54M)7.16M297K(39K)(44K)
Net Change in Cash158.33M36.37M(131.45M)(22.82M)(31.85M)
Free Cash Flow10.99M31.53M(56.25M)(71.3M)13.29M

InterCure Ltd.

NASDAQ:INCR

Intrinsic Alpha fair value

Locked

Current Price

$3.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.